Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BK4139 Biotechnology

Closed 03-11 16:00:00 EDT

73.61

-0.40

-0.53%

High74.29	Low73.34	Vol1.04B
Open74.00	D1 Closing74.00	Amplitude1.29%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O15.82B	T/O Rate--	Tradable Shares0.00
P/B7.181659	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BK4139","market":"US","secType":"PLATE","nameCN":"Biotechnology","latestPrice":73.60753,"timestamp":1773259199999,"preClose":74.00321,"halted":0,"volume":1039883429,"delay":0,"changeRate":-0.005347,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":-0.395683,"latestTime":"03-11 16:00:00 EDT","open":74.00335,"high":74.29178,"low":73.3364,"amount":15823358371.281454,"amplitude":0.01291,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1773273600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":7.181659,"peRate":-188.024099,"turnoverRate":0.030887,"increases":180,"decrements":313,"flats":20,"marketCap":1898500718739.9375,"floatMarketCap":1714025885441.5},"requestUrl":"/m/hq/s/BK4139/tweets","defaultTab":"tweets","newsList":[{"id":"2618786339","title":"Nutra Pharma Q1 net loss rises 229% to USD 1.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618786339","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618786339?lang=en_us&edition=fundamental","pubTime":"2026-03-12 03:23","pubTimestamp":1773257015,"startTime":"0","endTime":"0","summary":"Nutra Pharma reported net sales to unrelated customers of USD 73,974 in Q1 2025, up 96% on higher private label customer order volumes and the timing of orders. Net sales to related party Avini Health were USD 36,420 in Q1 2025. Selling, general and administrative expenses rose 27% to USD 418,150, driven by higher officer compensation and increased professional fees tied to the resumption of SEC filing activities. Net loss was USD 1.4 million in Q1 2025. The company said it raised USD 423,556 through convertible notes in Q1 2025 and estimates it will require about USD 1.2 million to fund existing operations over the next 12 months.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nutra Pharma Corporation published the original content us","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL3FpWN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NPHC","BK4139"],"gpt_icon":0},{"id":"2618978368","title":"Tevogen Bio Holdings Inc - Evaluating Acquisition of Sciometrix and Clinicus Platform for Long Covid Monitoring","url":"https://stock-news.laohu8.com/highlight/detail?id=2618978368","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618978368?lang=en_us&edition=fundamental","pubTime":"2026-03-12 03:15","pubTimestamp":1773256542,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nFWN3ZZ11G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TVGNW","TVGN"],"gpt_icon":0},{"id":"2618978365","title":"Tevogen accelerates TVGN 489 Long COVID program as HLA coverage reaches 65% of U.S. population","url":"https://stock-news.laohu8.com/highlight/detail?id=2618978365","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618978365?lang=en_us&edition=fundamental","pubTime":"2026-03-12 03:15","pubTimestamp":1773256525,"startTime":"0","endTime":"0","summary":"Tevogen said it is accelerating its Biotech and Digital Health verticals to move investigational TVGN 489 into its next clinical phase. Tevogen cited proof-of-concept data showing 100% of treated high-risk patients did not develop Long COVID. The company said identifying five additional HLA targets expanded potential eligibility for TVGN 489 to about 65% of the U.S. population. Tevogen also said it is evaluating the acquisition of Sciometrix and its Clinicus platform for real-world monitoring and data collection in future trials.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL2CYkwn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4585","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU0314104364.USD","LU2210149790.SGD","LU2210150020.SGD","SG9999014039.USD","BK4139","LU2095319765.USD","IE00BKPKM429.USD","BK4588","TVGN","BK4112","SG9999014013.SGD","NDAQ","SG9999014021.USD","SG9999014005.SGD"],"gpt_icon":0},{"id":"2618197852","title":"Solid Biosciences Touts Encouraging Results For Duchenne Gene Therapy, FDA Talks Planned","url":"https://stock-news.laohu8.com/highlight/detail?id=2618197852","media":"Benzinga_recent_news","labels":["policyRegulatory","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618197852?lang=en_us&edition=fundamental","pubTime":"2026-03-12 03:14","pubTimestamp":1773256440,"startTime":"0","endTime":"0","summary":"Solid Biosciences stock fell 8% after new SGT-003 Duchenne trial data. Investors remain cautious despite promising results and FDA plans.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/11/Gene-therapy.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/11/Gene-therapy.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/biotech/26/03/51197197/solid-biosciences-touts-encouraging-results-for-duchenne-gene-therapy-fda-talks-planned","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/biotech/26/03/51197197/solid-biosciences-touts-encouraging-results-for-duchenne-gene-therapy-fda-talks-planned","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4585","SMA","BK4139","BK4588","SLDB","BK4217","LABU"],"gpt_icon":0},{"id":"2618204409","title":"SAB Biotherapeutics Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2618204409","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618204409?lang=en_us&edition=fundamental","pubTime":"2026-03-12 02:50","pubTimestamp":1773255000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SABS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 11, 2026 14:50 ET (18:50 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SABS","BK4139"],"gpt_icon":0},{"id":"2618792003","title":"Voyager Therapeutics: Advancing Tau-Targeted Gene Therapy with Multiple Near-Term Catalysts and Attractive Risk-Reward","url":"https://stock-news.laohu8.com/highlight/detail?id=2618792003","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618792003?lang=en_us&edition=fundamental","pubTime":"2026-03-12 02:45","pubTimestamp":1773254723,"startTime":"0","endTime":"0","summary":"Analyst Yun Zhong of Wedbush maintained a Buy rating on Voyager Therapeutics, with a price target of $8.00. Yun Zhong has given his Buy rating due ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/voyager-therapeutics-advancing-tau-targeted-gene-therapy-with-multiple-near-term-catalysts-and-attractive-risk-reward-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/voyager-therapeutics-advancing-tau-targeted-gene-therapy-with-multiple-near-term-catalysts-and-attractive-risk-reward-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYGR","BK4139"],"gpt_icon":0},{"id":"2618920248","title":"Why Is Acurx Pharmaceuticals Stock Up Over 105% Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2618920248","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618920248?lang=en_us&edition=fundamental","pubTime":"2026-03-12 02:45","pubTimestamp":1773254700,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals Inc shares are trading sharply higher Wednesday afternoon despite a lack of company-specific news during the session.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/11/Woman-Hand-Holding-Healthcare-Medical-Ic_0.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/11/Woman-Hand-Holding-Healthcare-Medical-Ic_0.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/26/03/51196489/why-is-acurx-pharmaceuticals-acxp-stock-up-over-105-today","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/03/51196489/why-is-acurx-pharmaceuticals-acxp-stock-up-over-105-today","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4139","ACXP","BK4539","BK4563"],"gpt_icon":0},{"id":"2618504920","title":"How FDA’s No-Advisory-Committee Path for MOLBREEVI Could Shape Savara (SVRA) Investors’ Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2618504920","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618504920?lang=en_us&edition=fundamental","pubTime":"2026-03-12 02:19","pubTimestamp":1773253177,"startTime":"0","endTime":"0","summary":"Savara recently reported that the FDA’s Day 74 Letter for its MOLBREEVI Biologics License Application for autoimmune pulmonary alveolar proteinosis indicated no Advisory Committee meeting is planned and confirmed a PDUFA target action date of August 22, 2026, while European and U.K. marketing applications are also progressing.\nThis combination of streamlined U.S. review signals and parallel regulatory filings in Europe and the U.K. underscores how central MOLBREEVI has become to Savara’s...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-svra/savara/news/how-fdas-no-advisory-committee-path-for-molbreevi-could-shap","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-svra/savara/news/how-fdas-no-advisory-committee-path-for-molbreevi-could-shap","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","SVRA","BK4588","BK4139","BK4211","LABU","ISBC"],"gpt_icon":0},{"id":"2618942920","title":"Regenxbio Reports Duchenne Gene Therapy Progress As Stock Slides On Mixed Signals","url":"https://stock-news.laohu8.com/highlight/detail?id=2618942920","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618942920?lang=en_us&edition=fundamental","pubTime":"2026-03-12 02:19","pubTimestamp":1773253140,"startTime":"0","endTime":"0","summary":"Regenxbio releases new Duchenne trial data showing improved motor function and stable heart measures in early-stage patients.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/11/Gene-therapy-research.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/11/Gene-therapy-research.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/biotech/26/03/51196009/regenxbio-reports-duchenne-gene-therapy-progress-as-stock-slides-on-mixed-signals","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/biotech/26/03/51196009/regenxbio-reports-duchenne-gene-therapy-progress-as-stock-slides-on-mixed-signals","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["PRGS","IE00BFMHRM44.USD","LU1815336091.USD","LU0029874061.USD","LU0390134368.USD","LU2065732104.USD","LU0128526141.USD","BK4505","BK4121","BK4585","BK4588","BK4097","CRL","BK4217","RGNX","BK4139","SMA","BK4563","LU0757428866.USD","BK4530"],"gpt_icon":0},{"id":"2618270909","title":"Ligand Pharmaceuticals Is A Low-Risk Way To Bet On Biopharma Growth: Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2618270909","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618270909?lang=en_us&edition=fundamental","pubTime":"2026-03-12 02:11","pubTimestamp":1773252660,"startTime":"0","endTime":"0","summary":"Bank of America starts coverage on Ligand with a Buy rating and $244 target, citing strong royalty portfolio and growth outlook.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/11/Munich--Bavaria--Germany---March-31-2023_1.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/11/Munich--Bavaria--Germany---March-31-2023_1.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/initiation/26/03/51195831/ligand-pharmaceuticals-is-a-low-risk-way-to-bet-on-biopharma-growth-analyst","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/initiation/26/03/51195831/ligand-pharmaceuticals-is-a-low-risk-way-to-bet-on-biopharma-growth-analyst","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4139","LU1559883803.SGD","BK4007","LGND","IE0009354923.USD","LU0566484027.USD"],"gpt_icon":0},{"id":"2618927441","title":"BRIEF-Bridgebio Pharma Plans To Submit NDA For BBP-418 To FDA In H1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2618927441","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618927441?lang=en_us&edition=fundamental","pubTime":"2026-03-12 02:07","pubTimestamp":1773252474,"startTime":"0","endTime":"0","summary":"BRIEF-Bridgebio Pharma Plans To Submit NDA For BBP-418 To FDA In H1 2026March 11  - BridgeBio Pharma Inc BBIO.O:BBP-418 DEMONSTRATES CONSISTENT EFFICACY AND FAVORABLE SAFETY PROFILE IN PHASE 3 FORTIFY INTERIM ANALYSIS IN LGMD2I/R9BRIDGEBIO PHARMA INC - TO SUBMIT NDA FOR BBP-418 TO FDA IN H1 2026BRIDGEBIO PHARMA INC - BBP-418 WELL TOLERATED WITH SAFETY PROFILE COMPARABLE TO PLACEBO ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nFWN3ZZ0OK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","BK4588","BBIO","BK4585"],"gpt_icon":0},{"id":"2618208259","title":"BridgeBio presents Phase 3 FORTIFY interim analysis results","url":"https://stock-news.laohu8.com/highlight/detail?id=2618208259","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618208259?lang=en_us&edition=fundamental","pubTime":"2026-03-12 02:06","pubTimestamp":1773252376,"startTime":"0","endTime":"0","summary":"BridgeBio (BBIO) Pharma presented additional “positive” data from the interim analysis of FORTIFY, the Phase 3 clinical trial of oral BBP-418, in i...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bridgebio-presents-phase-3-fortify-interim-analysis-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bridgebio-presents-phase-3-fortify-interim-analysis-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BBIO","BK4585","BK4139","BK4505"],"gpt_icon":0},{"id":"2618927600","title":"BridgeBio Pharma Inc - to Submit Nda for Bbp-418 to FDA in H1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2618927600","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618927600?lang=en_us&edition=fundamental","pubTime":"2026-03-12 02:00","pubTimestamp":1773252029,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nFWN3ZZ0OK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4139","BK4588","BBIO","BK4505"],"gpt_icon":0},{"id":"2618592792","title":"BridgeBio Pharma Inc - Bbp-418 Well Tolerated With Safety Profile Comparable to Placebo","url":"https://stock-news.laohu8.com/highlight/detail?id=2618592792","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618592792?lang=en_us&edition=fundamental","pubTime":"2026-03-12 02:00","pubTimestamp":1773252029,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nFWN3ZZ0OK:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4588","BK4505","BK4139","BBIO"],"gpt_icon":0},{"id":"2618279889","title":"Bbp-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 Fortify Interim Analysis in Lgmd2i/R9","url":"https://stock-news.laohu8.com/highlight/detail?id=2618279889","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618279889?lang=en_us&edition=fundamental","pubTime":"2026-03-12 02:00","pubTimestamp":1773252029,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nFWN3ZZ0OK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4585","BBIO","BK4505","BK4588"],"gpt_icon":0},{"id":"2618792793","title":"BridgeBio reports Phase 3 FORTIFY interim results showing BBP-418 improved 100-meter timed test by 31 seconds at 12 months","url":"https://stock-news.laohu8.com/highlight/detail?id=2618792793","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618792793?lang=en_us&edition=fundamental","pubTime":"2026-03-12 02:00","pubTimestamp":1773252023,"startTime":"0","endTime":"0","summary":"BridgeBio reported interim results from the Phase 3 FORTIFY trial of oral BBP-418 in limb-girdle muscular dystrophy type 2I/R9, which were presented in a late-breaking oral presentation at the MDA Clinical and Scientific Conference. In the interim analysis, participants on BBP-418 showed a reduction in serum creatine kinase, with 60% reaching levels within 2x the upper limit of normal at 12 months. The 100-meter timed test separated from placebo as early as three months, and at 12 months the BBP-418 group completed the test about 31 seconds faster than placebo. Safety findings showed treatment-emergent adverse events in 93% of the BBP-418 arm and 100% of the placebo arm, with grade 3 or higher events occurring in 5% of each group. BridgeBio said it plans to submit a U.S. NDA for traditional approval in the first half of 2026, with a U.S. launch anticipated in late 2026 or early 2027.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDLb2McNj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","SG9999014021.USD","LU2210150020.SGD","SG9999014005.SGD","SG9999014039.USD","BK4505","IE00B3QW5Z07.USD","LU2095319765.USD","IE00B64PRP62.GBP","BK4585","NDAQ","BK4588","IE00BGHQF748.EUR","BK4139","LU2210149790.SGD","SG9999014013.SGD","BBIO","LU0314104364.USD","BK4112"],"gpt_icon":0},{"id":"2618271509","title":"Ovid Therapeutics (OVID) Receives a Buy from B. Riley Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2618271509","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618271509?lang=en_us&edition=fundamental","pubTime":"2026-03-12 01:45","pubTimestamp":1773251117,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Madison Elsaadi from B. Riley Securities reiterated a Buy rating on Ovid Therapeutics, with a price target of $5.00...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/ovid-therapeutics-ovid-receives-a-buy-from-b-riley-securities-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/ovid-therapeutics-ovid-receives-a-buy-from-b-riley-securities-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OVID","BK4139"],"gpt_icon":0},{"id":"2618927195","title":"Canadian Critical Minerals Details Insider Participation and Finder Fees in LIFE Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2618927195","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618927195?lang=en_us&edition=fundamental","pubTime":"2026-03-12 01:43","pubTimestamp":1773251025,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Canadian Critical Minerals ( ($TSE:CCMI) ). Canadian Critical Minerals Inc. has provided an update on its previ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/canadian-critical-minerals-details-insider-participation-and-finder-fees-in-life-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/canadian-critical-minerals-details-insider-participation-and-finder-fees-in-life-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MTX","BK4173","LIFE","BK4109","BK4563","BK4139"],"gpt_icon":0},{"id":"2618922059","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2618922059","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618922059?lang=en_us&edition=fundamental","pubTime":"2026-03-12 01:41","pubTimestamp":1773250876,"startTime":"0","endTime":"0","summary":"Oracle's (ORCL) fiscal Q3 results surpassed Wall Street's estimates, buoyed by strong demand for cloud computing amid an AI boom.Shares jumped 9% as intraday trading volume climbed to more than 61.2 m","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0081259029.USD","BK4534","LU0210536198.USD","LU1366333091.USD","LU0648001328.SGD","LU0985489474.SGD","LU1069347547.HKD","LU2237957902.USD","LU0198837287.USD","ORCL","IE0004445239.USD","ORCX","IE00B775SV38.USD","LU0157215616.USD","LU0070302665.USD","ORCS","SG9999003800.SGD","ORCU","LU0175139822.USD","IE0009356076.USD","LU1934455863.HKD","LU0320765489.SGD","BK4192","LU2250418816.HKD","LU1934455277.USD","BK4528","SG9999011175.SGD","BK4581","LU2237957811.SGD","LU2108987350.USD","IE00BLSP4452.SGD","IE00B5949003.HKD","LU1852331112.SGD","LU2087625088.SGD","LU1720051017.SGD","LU2326559502.SGD","LU2360106780.USD","LU0348723411.USD","LU0323591593.USD","LU0130102774.USD","LU0965508806.USD","LU1935042488.USD","IE00B3S45H60.SGD","LU1642822529.SGD","IE00BBT3K403.USD","LU1003077747.HKD","BK4588","LU2458330169.SGD","LU1548497426.USD","LU1366192091.USD","BK4563","LU0444971666.USD","LU0949170772.SGD","IE00B19Z3581.USD","LU0719512351.SGD","LU2357305700.SGD","LU0476273544.USD","LU0433182093.SGD","LU0980610538.SGD","BK4538","LU2860962120.EUR","LU0738911758.USD","IE00BMPRXN33.USD","LU1935043023.USD","LU1989764748.USD","LU1935042991.SGD","LU0234572021.USD","BK4139","LU1489326972.SGD","LU1989764664.SGD","LU0417517546.SGD","LU0957808578.USD","LU0353189763.USD","LU1989772923.USD","IE00BMPRXR70.SGD","LU0965509010.AUD","IE00BN8TJ469.HKD","LU0314106906.USD","IE00BLSP4239.USD","LU1720051108.HKD","LU1035773651.USD","LU0444973449.USD","IE00B7SZLL34.SGD","LU2458330243.SGD","LU0861579265.USD","BK4533","BK4585","LU1037948897.HKD","LU1429558221.USD","LU1935042215.USD","BODI","BK4568","LU1815336760.USD","LU0208291251.USD","LU2054465674.USD","BK4097","SG9999001424.SGD","LU0965509101.SGD","LU1506573853.SGD","IE00BMPRXQ63.HKD","LU0889565833.HKD","LU0353189680.USD","LU1435385759.SGD","BK4516","OCGN","LU1989772840.SGD","LU1037948541.HKD","LU0545039389.USD","LU2746668974.SGD","LU2236285917.USD","LU0553294199.USD","LU0289960550.SGD","LU0109392836.USD","LU2896262040.SGD","LU1934455194.USD","LU1201861249.SGD","LU0068578508.USD","LU0256863811.USD","LU1935043536.SGD","LU2746668461.USD","LU2543165471.USD","LU1691799644.USD","LU1803068979.SGD","BK4543","LU0082616367.USD","IE0002270589.USD","LU0661504455.SGD","LU0056508442.USD","LU0878866978.SGD","LU0234570918.USD","LU0965509283.SGD","IE00B19Z3B42.SGD"],"gpt_icon":1},{"id":"2618222499","title":"Sector Update: Health Care Stocks Decline Wednesday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2618222499","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618222499?lang=en_us&edition=fundamental","pubTime":"2026-03-12 01:38","pubTimestamp":1773250691,"startTime":"0","endTime":"0","summary":"Health care stocks were slipping Wednesday afternoon, with the NYSE Health Care Index down 0.3% and the State Street Health Care Select Sector SPDR ETF  easing 0.2%.The iShares Biotechnology ETF  decreased 0.7%.In corporate news, Stryker  is facing a global outage across its systems, and staff and contractors have said an Iran-linked hacking group's logo has appeared on login pages, The Wall Street Journal reported. Stryker shares were down 3.9%.Sonida Senior Living  said Wednesday it has completed its merger with CNL Healthcare Properties in a cash-and-stock deal valued about $1.8 billion. Sonida shares were falling over 6%.Kala Bio  shares jumped 24% after the company said its Researgency.ai platform is now live, with the first AI agent expected to be deployed in about 14 days.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","LU1983299246.USD","BK4082","KALA","LU2404859667.USD","SNDA","BK4504","LU2362540622.SGD","LU0882574055.USD","GB00B4LPDJ14.GBP","LU0114720955.EUR","LU0432979614.USD","BK4139","XLV","BK4185","LU2362541513.USD","GB00B4QBRK32.GBP","IBB","LU2089984988.USD","LU2362541273.HKD","LU0690374961.EUR","SYK","LU2324357040.USD","LU2404859741.USD","LU2468319806.SGD","LU0528227936.USD","LU0690374615.EUR","BK4588","BK4581","BK4566","LABU","LU1791710400.SGD","BK4585","LU1791710582.SGD","LU0289739699.SGD","LU0058720904.USD","XBI"],"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0046},{"period":"1month","weight":-0.0195},{"period":"3month","weight":-0.0151},{"period":"6month","weight":0.0297},{"period":"1year","weight":0.208},{"period":"ytd","weight":-0.007}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"name":"BK4139","nameEN":"BK4139"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Biotechnology(BK4139) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Biotechnology,BK4139,Biotechnology股票,Biotechnology股票老虎,Biotechnology股票老虎国际,Biotechnology行情,Biotechnology股票行情,Biotechnology股价,Biotechnology股市,Biotechnology股票价格,Biotechnology股票交易,Biotechnology股票购买,Biotechnology股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Biotechnology(BK4139) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction